@article{WaeckerleMen2006-12Dendr-22115,
  year={2006},
  doi={10.1007/s00262-006-0157-3},
  title={Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma},
  number={12},
  volume={55},
  issn={0340-7004},
  journal={Cancer Immunology, Immunotherapy},
  pages={1524--1533},
  author={Waeckerle-Men, Ying and Uetz-von Allmen, Edith and Fopp, Markus and Moos, Roger von and Böhme, Christel and Schmid, Hans-Peter and Ackermann, Daniel and Cerny, Thomas and Ludewig, Burkhard and Gröttrup, Marcus and Gillessen, Silke}
}

<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/22115">
    <dc:contributor>Uetz-von Allmen, Edith</dc:contributor>
    <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/22115"/>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Ludewig, Burkhard</dc:contributor>
    <dc:creator>Moos, Roger von</dc:creator>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Böhme, Christel</dc:creator>
    <dc:rights>terms-of-use</dc:rights>
    <dc:language>eng</dc:language>
    <dc:contributor>Moos, Roger von</dc:contributor>
    <dcterms:title>Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma</dcterms:title>
    <dc:contributor>Gröttrup, Marcus</dc:contributor>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/22115/2/Waeckerle-Men_221156.pdf"/>
    <dc:creator>Ackermann, Daniel</dc:creator>
    <dc:contributor>Gillessen, Silke</dc:contributor>
    <dcterms:bibliographicCitation>Cancer Immunology, Immunotherapy ; 55 (2006), 12. - S. 1524-1533</dcterms:bibliographicCitation>
    <dc:contributor>Cerny, Thomas</dc:contributor>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/22115/2/Waeckerle-Men_221156.pdf"/>
    <dc:contributor>Böhme, Christel</dc:contributor>
    <dc:creator>Fopp, Markus</dc:creator>
    <dc:contributor>Fopp, Markus</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-02-25T12:29:48Z</dcterms:available>
    <dcterms:issued>2006-12</dcterms:issued>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <dc:creator>Gillessen, Silke</dc:creator>
    <dc:creator>Waeckerle-Men, Ying</dc:creator>
    <dc:contributor>Ackermann, Daniel</dc:contributor>
    <dc:contributor>Waeckerle-Men, Ying</dc:contributor>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Ludewig, Burkhard</dc:creator>
    <dc:contributor>Schmid, Hans-Peter</dc:contributor>
    <dc:creator>Gröttrup, Marcus</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2013-02-25T12:29:48Z</dc:date>
    <dc:creator>Schmid, Hans-Peter</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Cerny, Thomas</dc:creator>
    <dcterms:abstract xml:lang="eng">Background: Dendritic cell (DC)-based immunotherapy is a promising approach to augment tumor antigen-specific T cell responses in cancer patients. However, tumor escape with down-regulation or complete loss of target antigens may limit the susceptibility of tumor cells to the immune attack. Concomitant generation of T cell responses against several immunodominant antigens may circumvent this potential drawback. In this trial, we determined the immunostimulatory capacity of autologous DC pulsed with multiple T cell epitopes derived from four different prostate-specific antigens in patients with advanced hormone-refractory prostate cancer.&lt;br /&gt;&lt;br /&gt;Patients and methods:&lt;br /&gt;Autologous DC of HLA-A*0201+ patients with hormone-refractory prostate cancer were loaded with antigenic peptides derived from prostate stem cell antigen (PSCA14–22), prostatic acid phosphatase (PAP299–307), prostate-specific membrane antigen (PSMA4–12), and prostate-specific antigen (PSA154–163). DC were intradermally applied six times at biweekly intervals followed-in the case of an enhanced immune response-by monthly booster injections. Immune monitoring during the time of ongoing vaccinations (12–59 weeks) included ex vivo ELISPOT measurements, MHC tetramer analysis and in vitro cytotoxicity assays.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Results: Of the initial six patients, three qualified for long-term multi-epitope DC vaccination. This regime was tolerated well by all three patients. The vaccination elicited significant cytotoxic T cell responses against all prostate-specific antigens tested. In addition, memory T cell responses against the control peptides derived from influenza matrix protein and tetanus toxoid were efficiently boosted. Clinically, the long-term DC vaccination was associated with an increase in PSA doubling time.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Conclusions: DC-based multi-epitope immunotherapy with repeated boosting in men with hormonerefractory prostate carcinoma is feasible and generates efficient cellular antitumor responses.</dcterms:abstract>
    <dc:creator>Uetz-von Allmen, Edith</dc:creator>
  </rdf:Description>
</rdf:RDF>